|
gptkbp:instanceOf
|
gptkb:HIV_drug
gptkb:drug
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AG14
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:boosts_plasma_concentration_of
|
gptkb:elvitegravir
gptkb:atazanavir
gptkb:darunavir
|
|
gptkbp:CASNumber
|
1004316-88-4
|
|
gptkbp:chemicalFormula
|
C40H53N7O5S2
|
|
gptkbp:combines
|
gptkb:elvitegravir
gptkb:atazanavir
gptkb:darunavir
emtricitabine
tenofovir
|
|
gptkbp:contraindication
|
severe liver impairment
concurrent use with certain drugs metabolized by CYP3A
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:drugClass
|
CYP3A inhibitor
pharmacokinetic enhancer
|
|
gptkbp:eliminationHalfLife
|
3-4 hours
|
|
gptkbp:indication
|
HIV-1 infection
|
|
gptkbp:KEGGID
|
D09968
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketed_in_combination_as
|
gptkb:Symtuza
gptkb:Genvoya
gptkb:Stribild
|
|
gptkbp:marketedAs
|
Tybost
|
|
gptkbp:mechanismOfAction
|
inhibits CYP3A enzymes
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
776.02 g/mol
|
|
gptkbp:not_an_antiretroviral
|
true
|
|
gptkbp:pregnancyCategory
|
B
|
|
gptkbp:PubChem_CID
|
25154713
28636916
CHEMBL2107728
DB09065
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
jaundice
rash
increased serum creatinine
|
|
gptkbp:synonym
|
gptkb:GS-9350
|
|
gptkbp:UNII
|
Q1ZXA2J1HF
|
|
gptkbp:usedFor
|
booster for HIV protease inhibitors
|
|
gptkbp:bfsParent
|
gptkb:DB06151
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cobicistat
|